Connective Portfolio Management LLC Sells 400 Shares of Natera, Inc. (NASDAQ:NTRA)

Connective Portfolio Management LLC lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,600 shares of the medical research company’s stock after selling 400 shares during the quarter. Natera accounts for 2.0% of Connective Portfolio Management LLC’s investment portfolio, making the stock its 20th largest holding. Connective Portfolio Management LLC’s holdings in Natera were worth $1,361,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of NTRA. Itau Unibanco Holding S.A. bought a new stake in shares of Natera in the 2nd quarter worth $28,000. Quarry LP boosted its holdings in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. Versant Capital Management Inc grew its position in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares in the last quarter. Covestor Ltd grew its position in Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the sale, the insider now directly owns 110,695 shares of the company’s stock, valued at $13,085,255.95. This trade represents a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 608 shares of Natera stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $73,422.08. Following the sale, the chief financial officer now owns 74,014 shares of the company’s stock, valued at approximately $8,937,930.64. The trade was a 0.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 123,409 shares of company stock valued at $20,045,631 in the last three months. Company insiders own 7.60% of the company’s stock.

Natera Price Performance

Natera stock opened at $170.35 on Thursday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a one year low of $59.80 and a one year high of $183.00. The business has a fifty day moving average price of $162.75 and a 200-day moving average price of $133.52.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the prior year, the business posted ($0.95) earnings per share. The company’s revenue was up 63.9% on a year-over-year basis. As a group, equities analysts anticipate that Natera, Inc. will post -1.61 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NTRA. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Craig Hallum raised their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. TD Cowen boosted their price target on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Robert W. Baird raised their price objective on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, Morgan Stanley boosted their target price on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $158.00.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.